Curarent Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 10 Months
- Last Filing with ROC 31 Mar 2021
- Revenue Growth 116.71%
- Profit Growth 98.73%
- Ebitda 0.20%
- Net Worth 1.28%
- Total Assets 7.97%
About Curarent Pharmaceutical
Curarent Pharmaceutical Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 April 2013 and has a history of 11 years and ten months. Its registered office is in Allahabad, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Wasim Ahamad and Nikhat Khan serve as directors at the Company.
Company Details
- Location
Allahabad, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233UP2013PTC055923
- Company No.
055923
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Apr 2013
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Curarent Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Wasim Ahamad  | Director | 02-Apr-2013 | Current |
| Nikhat Khan | Director | 02-Apr-2013 | Current |
Financial Performance of Curarent Pharmaceutical.
Curarent Pharmaceutical Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 116.71% increase. The company also saw a substantial improvement in profitability, with a 98.73% increase in profit. The company's net worth moved up by a moderate rise of 1.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Curarent Pharmaceutical?
Unlock access to Curarent Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Curarent Pharmaceutical?
Unlock and access historical data on people associated with Curarent Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Curarent Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Curarent Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.